ASMB
NASDAQAssembly Biosciences Inc.
News · 26 weeks48+100%
2026-03-012026-08-23
Mix2290d
- Insider13(59%)
- Other5(23%)
- SEC Filings4(18%)
Latest news
25 items- SECSEC Form S-8 filed by Assembly Biosciences Inc.S-8 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- SECSEC Form 10-Q filed by Assembly Biosciences Inc.10-Q - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- SECAssembly Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- PRAssembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 – – Cash runway projected into 2029, including first $75 million Gilead collaboration extension payment due in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics target
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Assembly Biosciences Inc.SCHEDULE 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Assembly Biosciences Inc.SCHEDULE 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
- INSIDERPFO and PAO Bjorkquist Jeanette M sold $674 worth of shares (29 units at $23.25), decreasing direct ownership by 0.20% to 14,560 units (SEC Form 4) (tax withholding)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERChief Medical Officer Gaggar Anuj was granted 14,000 shares, increasing direct ownership by 49% to 42,688 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERChief Manufacturing Officer White Nicole S was granted 14,000 shares, increasing direct ownership by 41% to 48,145 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Mchutchison John G4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Mahony Susan4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson-Pratt Lisa4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Houghton Michael4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Consylman Gina4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERSEC Form 4 filed by Director Altig Anthony E4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERPFO and PAO Bjorkquist Jeanette M was granted 3,500 shares, increasing direct ownership by 32% to 14,589 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERChief Scientific Officer Delaney William E Iv was granted 14,000 shares, increasing direct ownership by 30% to 60,330 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- INSIDERCEO and President Okazaki Jason A was granted 50,750 shares, increasing direct ownership by 45% to 163,354 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- SECAssembly Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- PRAssembly Biosciences Announces Upcoming Investor Conference PresentationsSOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming investor conferences: Jefferies 2026 Global Healthcare ConferenceDate: June 3, 2026Time: 4:20 p.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: June 8, 2026Time: 8:40 a.m. ET To register for either webcast, please visit the Events and Presentations section of Assembly Bio's website at: https://investor.assemblybio.com/events-presentations. A replay will be accessible following each
- INSIDERLarge owner Gilead Sciences, Inc. was granted 471,698 shares, increasing direct ownership by 10% to 4,977,089 units (SEC Form 4)4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Assembly Biosciences Inc.SCHEDULE 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
- SECAssembly Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
- PRAssembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesSOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of 3,924,624 shares of its common stock at an offering price per share of common stock of $26.50, which includes the exercise in full by the underwriters of their option to purchase 566,040 additional shares of common stock. In addition, and in lieu of common stock, Assembly Bio sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 415,000 shares of common stock a
- SECSEC Form 424B5 filed by Assembly Biosciences Inc.424B5 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
ASMB FAQ
7 questionsWhat does Assembly Biosciences Inc. do?
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well...Where does ASMB stock trade?
Assembly Biosciences Inc. (ASMB) is listed on NASDAQ.What sector and industry is ASMB in?
Assembly Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Assembly Biosciences Inc. go public?
Assembly Biosciences Inc. (ASMB) completed its IPO in 2010.What are analysts saying about ASMB?
Assembly Biosciences Inc. has had 6 recent analyst actions on file. The most recent action was from Citizens JMP: Mkt Outperform with a $3800.00 price target on 2025-09-24.What companies are similar to ASMB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ASMB side-by-side with any of them on Quantisnow.How can I track ASMB on Quantisnow?
Quantisnow aggregates Assembly Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASMB to receive live email and push alerts on every new disclosure.